Targeting C-reactive protein for the treatment of cardiovascular disease

Nature

Volumn 440, Issue 7088, 2006, Pages 1217-1221

  Pepys, Mark B ^a   Hirschfield, Gideon M ^a,e   Tennent, Glenys A ^a   Gallimore, J Ruth ^a   Kahan, Melvyn C ^a   Bellotti, Vittorio ^a,f   Hawkins, Philip N ^a   Myers, Rebecca M ^b   Smith, Martin D ^b   Polara, Alessandra ^b   Cobb, Alexander J A ^a,g   Ley, Steven V ^b   Aquilina, J Andrew ^b,h   Robinson, Carol V ^b   Sharif, Isam ^c   Gray, Gillian A ^c   Sabin, Caroline A ^a   Jenvey, Michelle C ^d   Kolstoe, Simon E ^d   Thompson, Darren ^d,i   Wood, Stephen P ^d   more..

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF READING   (United Kingdom)

^h UNIVERSITY OF WOLLONGONG   (Australia)

ⁱ UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR SYSTEM; DISEASES; MEDICAL PROBLEMS; NEUROLOGY; TISSUE;

CARDIOPROTECTIVE TREATMENT; LIGAND-BINDING; NEUROPROTECTIVE TREATMENTS; THERAPEUTIC INHIBITION;

PROTEINS;

1,6 BIS(PHOSPHOCHOLINE) HEXANE; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CHOLINE DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; HEALTH AND DISEASE; INHIBITION; LIGAND; NEUROLOGY; PROTEIN; SURVIVAL;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CROSS LINKING; RAT; STROKE; TISSUE INJURY;

ANIMALIA;

EID: 33646366683     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04672     Document Type: Article

References (23)

1. Pepys, M. B. & Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 111, 1805-1812 (2003).
2. Griselli, M. et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 190, 1733-1739 (1999).
3. Gill, R., Kemp, J. A., Sabin, C. & Pepys, M. B. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J. Cereb. Blood Flow Metob. 24, 1214-1218 (2004).
4. de Beer, F. C. et al. Isolation and characterisation of C-reactive protein and serum amyloid P component in the rat. Immunology 45, 55-70 (1982).
5. Thompson, D., Pepys, M. B. & Wood, S. P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7, 169-177 (1999).
6. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
7. Eda, S., Kaufmann, J., Roos, W. & Pohl, S. Development of a new microparticle-enhanced turbidometric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J. Clin. Lab. Anal. 12, 137-144 (1998).
8. Kushner, I., Broder, M. L. & Karp, D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J. Clin. Invest. 61, 235-242 (1978).
9. de Beer, F. C. et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br. Heart J. 47, 239-243 (1982).
10. Taylor, K. E., Giddings, J. C. & van den Berg, C. W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 25, 1225-1230 (2005).
11. Pepys, M. B. CRP or not CRP? That is the question. Arterioscler. Thromb. Vasc. Biol. 25, 1091-1094 (2005).
12. Pepys, M. B. et al. Pro-inflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products not by C-reactive protein itself. Circ. Res. 97, e97-103 (2005).
13. Clapp, B. R. et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111, 1530-1536 (2005).
14. Hirschfield, G. M. et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA 102, 8309-8314 (2005).
15. Ledue, T. B. et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann. Clin. Biochem. 35, 745-753 (1998).
16. Nelson, S. R. et al. Serum amyloid P component in chronic renal failure and dialysis. Clin. Chim. Acta 200, 191-200 (1991).
17. Bhakdi, S., Torzewski, M., Klouche, M. & Hemmes, M. Complement and atherogenesis. Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 19, 2348-2354 (1999).
18. Hawkins, P. N., Tennent, G. A., Woo, P. & Pepys, M. B. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin. Exp. Immunol. 84, 308-316 (1991).
19. B receptors that modulate contraction. Br. J. Pharmacol. 130, 1735-1744 (2000).
20. Miller, A. A., Megson, I. L. & Gray, G. A. Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. Br. J. Pharmacol. 131, 29-36 (2000).
21. Mora, A. et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 22, 4666-4676 (2003).
22. Denvir, M. A. et al. Influence of scanning frequency and ultrasonic contrast agent on reproducibility of left ventricular measurements in the mouse. J. Am. Soc. Echocardiogr. 18, 155-162 (2005).
23. DeLano, W. L. The PyMOL Molecular Graphics System http://www.pymol.org (2002).